Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer.
Aged
Biomarkers, Tumor
/ analysis
Blotting, Western
Colorectal Neoplasms
/ chemistry
Female
GPI-Linked Proteins
/ analysis
Humans
Immunohistochemistry
Male
Mesothelin
Microsatellite Instability
Middle Aged
Neoplasm Staging
Real-Time Polymerase Chain Reaction
Retrospective Studies
Time Factors
Treatment Outcome
Colorectal cancer
Glycoprotein
Immunohistochemistry
Mesothelin
Prognosis
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
18
10
2018
accepted:
17
12
2018
revised:
08
12
2018
pubmed:
4
1
2019
medline:
10
4
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
Mesothelin (MSLN) is a cell-surface glycoprotein present on mesothelial cells and in many cancers, where expression is generally associated with an unfavorable prognosis. The clinical significance and pathological characteristics of MSLN expression were evaluated by immunohistochemical staining of tissues from 530 stage ΙΙ/ΙΙΙ colorectal cancer (CRC) patients with R0 resection. Eighty-eight (16.6%) were MSLN-positive; 33 (37.5%) showed a luminal staining pattern whereas 55 (62.5%) showed a non-luminal staining pattern. MSLN expression, including the luminal and non-luminal staining patterns, was associated with shorter cancer-specific survival (CSS) period in stage ΙΙ (n = 314, P = 0.024) and stage ΙΙΙ (n = 216, P = 0.0002) CRC patients. The non-luminal staining pattern was correlated with poor prognosis in stage ΙΙ (P = 0.0006) and III (P < 0.0001) CRC, but a luminal staining pattern was not significantly correlated with prognosis. Cox's multivariate analysis revealed that a non-luminal staining pattern was associated with CSS independently of other conventional parameters in stage II (P = 0.040, hazard ratio (HR) = 2.92) and III (P = 0.020, HR = 2.13) CRC patients. Immunohistochemical evaluation of MSLN expression was helpful in the prediction of patient prognosis in stage II/III CRC.
Identifiants
pubmed: 30603773
doi: 10.1007/s00428-018-02514-4
pii: 10.1007/s00428-018-02514-4
doi:
Substances chimiques
Biomarkers, Tumor
0
GPI-Linked Proteins
0
MSLN protein, human
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-307Références
Lancet. 2000 Mar 25;355(9209):1041-7
pubmed: 10744089
J Clin Oncol. 2000 Aug;18(16):2938-47
pubmed: 10944126
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
Cancer. 2002 Dec 1;95(11):2422-30
pubmed: 12436451
Mod Pathol. 2003 Mar;16(3):192-7
pubmed: 12640097
Hum Pathol. 2003 Jun;34(6):605-9
pubmed: 12827615
Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43
pubmed: 14530656
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42
pubmed: 15217923
Lab Invest. 2005 Feb;85(2):257-66
pubmed: 15516972
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7
pubmed: 16082249
Clin Cancer Res. 2005 Sep 1;11(17):6342-51
pubmed: 16144939
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31
pubmed: 16467095
Mol Cancer. 2006 Oct 26;5(1):50
pubmed: 17067392
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605
Clin Cancer Res. 2007 Sep 1;13(17):5144-9
pubmed: 17785569
Mol Cancer Ther. 2008 Feb;7(2):286-96
pubmed: 18281514
Nanomedicine. 2008 Dec;4(4):295-301
pubmed: 18691948
Mol Cancer Res. 2008 Nov;6(11):1755-65
pubmed: 19010822
J Biol Chem. 2009 Feb 6;284(6):3739-49
pubmed: 19075018
J Clin Oncol. 2009 Feb 10;27(5):663-71
pubmed: 19114683
Br J Cancer. 2009 Apr 7;100(7):1144-53
pubmed: 19293794
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Clin Cancer Res. 2009 Aug 15;15(16):5274-9
pubmed: 19671873
Clin Cancer Res. 2010 Dec 15;16(24):6132-8
pubmed: 21037025
Carcinogenesis. 2011 Jul;32(7):1013-24
pubmed: 21515913
J Surg Oncol. 2012 Feb;105(2):195-9
pubmed: 21780126
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):482-6
pubmed: 22237988
Cancer Sci. 2012 Apr;103(4):739-46
pubmed: 22320398
Br J Cancer. 2012 Jun 26;107(1):137-42
pubmed: 22644300
J Gastroenterol. 2014 Jan;49(1):81-92
pubmed: 23512344
Cancer Immunol Res. 2014 Feb;2(2):112-20
pubmed: 24579088
Jpn J Clin Oncol. 2015 Jun;45(6):533-40
pubmed: 25770060
Int J Clin Oncol. 2015 Apr;20(2):207-39
pubmed: 25782566
Appl Immunohistochem Mol Morphol. 2016 Apr;24(4):246-52
pubmed: 26894650
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591